Lung cancer: open trials in Peru

14 open trials have a site in Peru. Registry data; only the trial team decides who can take part.

NCT05920356
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Trial Treatment · Phase 3 · Amgen
Centro de Investigacion Vallesur, Arequipa · Hospital Nacional Adolfo Guevara Velasco, Cusco · Unidad de Investigación Clínica Internacional Sede San Borja, Lima · Hospital de Apoyo Departamental Maria Auxiliadora, Lima · Oncosalud, Lima
Registry updated 2026-11-06
NCT06170788
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Clinica Vallesur - AUNA (Site 0854), Arequipa · IPOR Instituto Peruano de Oncología & Radioterapia-Centro de Investigación (Site 0851), Lima · Hospital Cayetano Heredia-Oncology (Site 0855), Lima · Instituto Neuro Cardiovascular de las Americas (Site 0856), Lima · INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS (Site 0850), Lima · Detecta Clínica (Site 0853), Surquillo
Registry updated 2026-11-03
NCT04613596
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Trial Treatment · Phase 2/3 · Mirati Therapeutics Inc.
Local Institution - Unk044, Arequipa · Local Institution - Unk023, Arequipa · Local Institution - Unk051, Arequipa · Local Institution - Unk040, Cusco · Local Institution - Unk022, Jesus Maria · Local Institution - Unk046, Lima · Local Institution - Unk031, Lima Cercado · Local Institution - Unk024, Miraflores · Local Institution - Unk071, San Isidro · Local Institution - Unk042, San Isidro · Local Institution - Unk054, Surquillo · Local Institution - Unk080, Trujillo
Registry updated 2026-10-30
NCT06623422
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Clínica Internacional - Sede San Borja (Site 2752), Lima · IPOR Instituto Peruano de Oncología & Radioterapia (Site 2755), Lima · Aliada (Site 2753), Lima · Detecta Clínica (Site 2751), Lima
Registry updated 2026-10-30
NCT06422143
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Clínicas AUNA Sede Chiclayo (Site 0604), Chiclayo · Oncosalud-Clinical Research (Site 0600), Lima · Hospital Militar Central Coronel Luis Arias Schereiber (Site 0602), Lima · Clínica San Antonio (Site 0606), Trujillo
Registry updated 2026-10-29
NCT06692738
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Trial Treatment · Phase 3 · AstraZeneca
Lima
Registry updated 2026-10-29
NCT06627647
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
Trial Treatment · Phase 3 · AstraZeneca
Lima
Registry updated 2026-10-28
NCT06996782
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Trial Treatment · Phase 1/2 · AstraZeneca
Lima
Registry updated 2026-10-28
NCT06345729
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
IPOR Instituto Peruano de Oncología & Radioterapia (Site 4301), Lima
Registry updated 2026-10-26
NCT07190248
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Hospital Nacional Edgardo Rebagliati Martins (Site 0903), Lima · Oncosalud (Site 0901), Lima · IPOR Instituto Peruano de Oncología & Radioterapia (Site 0902), Lima
Registry updated 2026-10-26
NCT07361510
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Trial Treatment · Phase 3 · Bristol-Myers Squibb
Lima · Lima · San Borja
Registry updated 2026-10-23
NCT06312137
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
IPOR Instituto Peruano de Oncología & Radioterapia-Centro de Investigación (Site 0604), Lima · Instituto Neuro Cardiovascular de las Americas (Site 0607), Lima · INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS-Medical Oncology (Site 0600), Lima · Oncosalud (Site 0602), Lima · Hospital Nacional Edgardo Rebagliati Martins-medical oncology (Site 0603), Lima
Registry updated 2026-10-15
NCT07128199
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Trial Treatment · Phase 3 · Taiho Oncology, Inc.
Hospital Nacional Arzobispo Loayza, Lima Cercado · Luis Alberto Vera Valdivia, San Borja · Clínicas Oncosalud Sede Guardia Civil, San Borja · IPOR - Instituto Peruano de Oncología & Radioterapia - Sede Principal, San Isidro · Detecta Clínica, Surquillo
Registry updated 2026-10-13
NCT07192991
Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America
Research · Latin American Cooperative Oncology Group
Oncosalud AUNA, Lima
Registry updated 2026-09-08

All Lung cancer trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error